Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome

BACKGROUND: The incidence of alloimmunisation in myelodysplastic syndromes (MDS) during the era of supportive treatment ranges from 9 to 56%. However, it is unknown if the widespread use of hypomethylating agents has changed the risk of immunisation. The aim of this study is to evaluate the impact o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Transfus
Main Authors: Ortiz, Sebastián, Orero, Maria T., Javier, Karla, Villegas, Carolina, Luna, Irene, Pérez, Pedro, Roig, Mónica, López, María, Costa, Sofía, Carbonell, Félix, Collado, Rosa, Ivars, David, Linares, Mariano
Formato: Artigo
Idioma:Inglês
Publicado em: Edizioni SIMTI - SIMTI Servizi Srl 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589710/
https://ncbi.nlm.nih.gov/pubmed/27416573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2016.0012-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados